Matthew Frigault, MD
Enriched profileAssistant Professor of Medicine, Harvard Medical School; Clinical Director, Cellular Immunotherapy Program, Mass General Cancer Center · Massachusetts General Hospital
Matthew Frigault is Assistant Professor of Medicine, Harvard Medical School; Clinical Director, Cellular Immunotherapy Program, Mass General Cancer Center at Massachusetts General Hospital. OpenAlex indexes 302 publications with 12,739 citations (h-index 48); ClinicalTrials.gov lists 7 registered studies with this person as an investigator.
Data verified 17 Oct 2026
Overview
Updated 17 Oct 2026
Matthew J. Frigault, MD, is Assistant Professor of Medicine, Harvard Medical School at Massachusetts General Hospital / Mass General Brigham. The public record shows 302 publications with 12,739 citations (h-index 48), centered on Leukemia (AML/ALL/CML/CLL), Lymphoma, Multiple Myeloma. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 19 companies.
- Most recent indexed publication: 2026 · Blood
- Top research focus: Leukemia (AML/ALL/CML/CLL)
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 19 companies
Generated from the cited public record · current as of 17 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 11 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 17 Oct 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- Emapalumab Prevention of CAR-T Cell Associated Toxicities
Sponsor: Marcela V. Maus, M.D.,Ph.D.
- CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Sponsor: Marcela V. Maus, M.D.,Ph.D.
Industry payments
Updated 17 Oct 2026
19 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca UK LimitedProgram year20251 payment
- Legend Biotech USA Inc.Program year20251 payment
- Gilead Sciences, Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
59.5%Short-acting sulfonamides59.5%Sulfamethoxazole-Trimethoprim100%Part D≥18 patientsDermatology
40.5%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor40.5%Acyclovir100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 17 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Stealth transgenes enable CAR-T cells to evade host immune responses.
Journal for immunotherapy of cancer
Article2024 - Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.
Blood advances
Clinical Trial2023
Online presence
Updated 17 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/matthew-frigault-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/MassGeneralBrigham/posts/matthew-frigault-md-inaugural-incumbent-of-the-john-and-ashley-ranelli-endowed-s/1160173909485228
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Instagram
instagram.com/p/DMdrkAVzp0u
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - LinkedIn
linkedin.com/posts/mass-general-brigham_matthew-frigault-md-inaugural-incumbent-activity-7353884159007694848-cMhH
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Matthew-J-Frigault-59350543
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 17 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneral.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneral.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneral.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneral.org ↗
- BA
College of the Holy Cross, magna cum laude
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneral.org ↗
Editorial & leadership roles
journal and society appointments- Clinical Director
Cellular Immunotherapy Program, Mass General Cancer Center (BMT & Cellular Therapy)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneral.org ↗ - Medical Oncologist
Hematologic Malignancy Program, Massachusetts General Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneral.org ↗
Awards & honors
honors on the public record- Inaugural John and Ashley Ranelli Endowed Scholar in Cancer Innovation
Massachusetts General Hospital ($1M endowed scholar position)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →giving.massgeneral.org ↗
Secondary affiliations
appointments beyond the home institution- Member
Dana-Farber/Harvard Cancer Center (DF/HCC) Leukemia Program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dfhcc.harvard.edu ↗ - Advisory Board
ImmunoFree
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →immunofree.com ↗
Media & interviews
press, podcasts and appearances- OncLive video interview series on CAR T-cell therapy in leukemia
lymphoma, and multiple myeloma (multiple appearances, incl. "Dr. Frigault on Toxicity Differences Among CAR T-Cell Products in Leukemias, Lymphomas")
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - "Updates in CAR T-Cell Therapy"
Mass General Advances in Motion video interview with Billy Costa
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneral.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
James Januzzi, MD
Massachusetts General Hospital
Maurizio Fava, MD
Massachusetts General Hospital
Steven Greenberg, MD
Massachusetts General Hospital
David Scadden, MD
Massachusetts General Hospital
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center